http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 22 Nov 2024 17:57:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/MYND+Life+Sciences+Announces+Strategic+Debt+Reduction+and+New+Board+Member+Appointment/24024174.html <p>Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - <b>MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) </b>("<b>MYND</b>" or the "<b>Company</b>"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial position and governance. These moves demonstrate a strong commitment to the company's vision and strategic plan to commercialize a diagnostic biomarker test for depression which is being initially developed for the purpose of diagnosing and monitoring those with major depressive disorder (MDD). </p><p><b>Debt Reduction</b></p><p>As part of our ongoing commitment to financial health and operational efficiency, MYND Life Sciences http://www.streetinsider.com/Press+Releases/MYND+Life+Sciences+Announces+Strategic+Debt+Reduction+and+New+Board+Member+Appointment/24024174.html Fri, 22 Nov 2024 17:57:00 -0500 MYNDF http://www.streetinsider.com/Newsfile/MYND+Life+Sciences+Announces+Strategic+Debt+Reduction+and+New+Board+Member+Appointment/24024174.html <p>Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - <b>MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) </b>("<b>MYND</b>" or the "<b>Company</b>"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial position and governance. These moves demonstrate a strong commitment to the company's vision and strategic plan to commercialize a diagnostic biomarker test for depression which is being initially developed for the purpose of diagnosing and monitoring those with major depressive disorder (MDD). </p><p><b>Debt Reduction</b></p><p>As part of our ongoing commitment to financial health and operational efficiency, MYND Life Sciences http://www.streetinsider.com/Newsfile/MYND+Life+Sciences+Announces+Strategic+Debt+Reduction+and+New+Board+Member+Appointment/24024174.html Fri, 22 Nov 2024 17:57:00 -0500 MYNDF http://www.streetinsider.com/Press+Releases/MYND+Life+Sciences+Announces+Proposed+Share+Issuance+to+Remove+Debenture+and+%243.440+M+in+debt+on+business/23968195.html <p>Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - <b>MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) </b>("<b>MYND</b>" or the "<b>Company</b>") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that subject to regulatory approval, it is proposing to issue 4 Million shares @ 0.71 per share to move $3.5 Million from its balance sheet, including the full restructure of an outstanding debenture on the business.</p><p>"We are pleased to announce this important agreement to restructure our balance sheet to enhance both current and prospective shareholder value and to align with http://www.streetinsider.com/Press+Releases/MYND+Life+Sciences+Announces+Proposed+Share+Issuance+to+Remove+Debenture+and+%243.440+M+in+debt+on+business/23968195.html Tue, 12 Nov 2024 20:05:00 -0500 MYNDF http://www.streetinsider.com/Newsfile/MYND+Life+Sciences+Announces+Proposed+Share+Issuance+to+Remove+Debenture+and+%243.440+M+in+debt+on+business/23968195.html <p>Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - <b>MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) </b>("<b>MYND</b>" or the "<b>Company</b>") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that subject to regulatory approval, it is proposing to issue 4 Million shares @ 0.71 per share to move $3.5 Million from its balance sheet, including the full restructure of an outstanding debenture on the business.</p><p>"We are pleased to announce this important agreement to restructure our balance sheet to enhance both current and prospective shareholder value and to align with http://www.streetinsider.com/Newsfile/MYND+Life+Sciences+Announces+Proposed+Share+Issuance+to+Remove+Debenture+and+%243.440+M+in+debt+on+business/23968195.html Tue, 12 Nov 2024 20:05:00 -0500 MYNDF